Abciximab

Title: Abciximab
CAS Registry Number: 143653-53-6
CAS Name: Anti-(human integrin aIIbb3) immunoglobulin G1 Fab fragment (human-mouse monoclonal c7E3 clone p7E3VHhCg1 g1-chain) disulfide with human-mouse monoclonal c7E3 clone p7E3VkhCk k-chain
Additional Names: c7E3 Fab
Trademarks: ReoPro (Lilly)
Literature References: Platelet aggregation inhibitor. Fab fragment of chimeric human-murine monoclonal antibody c7E3 directed against the human platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor. Chimeric fragment consists of the variable regions of murine 7E3 reconstructed with human constant regions of the Fab fragment. Mol wt ~47,600. Prepn: B. S. Coller, D. M. Knight, WO 9512412 (1995 to Centocor and Res. Found. State Univ. New York); D. M. Knight et al., Mol. Immunol. 32, 1271 (1995). Pharmacology: C. Kohmura et al., Arterioscler. Thromb. 13, 1837 (1993). Clinical pharmacodynamics: J. E. Tcheng et al., Circulation 90, 1757 (1994). Clinical studies as adjunct in prevention of ischemic complications associated with coronary revascularization: EPIC Investigators, N. Engl. J. Med. 330, 956 (1994); EPILOG Investigators, ibid. 336, 1689 (1997). Review of development, binding studies and preclinical testing: R. E. Jordan et al. in Adhesion Receptors as Therapeutic Targets, M. A. Horton, Ed. (CRC Press, Boca Raton, 1996) p 281-305; of pharmacology and clinical efficacy: R. H. Foster, L. R. Wiseman, Drugs 56, 629-665 (1998).
Therap-Cat: Antithrombotic.
Keywords: Antithrombotic.
Abecarnil Abetimus Sodium Abietic Acid Abikoviromycin Abrin

Abciximab ?
Monoclonal antibody
Type Fab fragment
Source Chimeric (mouse/human)
Target CD41 7E3
Clinical data
Trade names Reopro
AHFS/Drugs.com monograph
Pregnancy cat. C (US)
Legal status  ?
Routes IV
Pharmacokinetic data
Half-life <10 min–30 min
Identifiers
CAS number 143653-53-6 YesY
ATC code B01AC13
DrugBank DB00054
UNII X85G7936GV YesY
KEGG D02778 YesY
ChEMBL CHEMBL1201584 N
Chemical data
Formula C2101H3229N551O673S15 
Mol. mass 47455.4 g/mol
 N (what is this?)  (verify)

Abciximab (previously known as c7E3 Fab), a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.[1]

While abciximab has a short plasma half-life, due to its strong affinity for its receptor on the platelets, it may occupy some receptors for weeks. In practice, platelet aggregation gradually returns to normal about 96 to 120 hours after discontinuation of the drug.(Tanguay, J.F., Eur Heart J 1999; 1 (suppl E): E27-E35 Abciximab is made from the Fab fragments of an immunoglobulin that targets the glycoprotein IIb/IIIa receptor on the platelet membrane.[2]